NCT00028366View on ClinicalTrials.gov

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 2005

Conditions
HIV Infections
Interventions
DRUG

Fosamprenavir

DRUG

Lopinavir/Ritonavir

DRUG

Ritonavir

DRUG

Tenofovir disoproxil fumarate

Trial Locations (13)

30308

The Ponce de Leon Ctr. CRS, Atlanta

37203

Vanderbilt Therapeutics CRS, Nashville

44106

Case CRS, Cleveland

46202

Indiana Univ. School of Medicine, Wishard Memorial, Indianapolis

Methodist Hosp. of Indiana, Indianapolis

94110

Ucsf Aids Crs, San Francisco

98104

University of Washington AIDS CRS, Seattle

432101228

The Ohio State Univ. AIDS CRS, Columbus

441091998

MetroHealth CRS, Cleveland

452670405

Univ. of Cincinnati CRS, Cincinnati

462025250

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

90033-1079

USC CRS, Los Angeles

Unknown

HIV Prevention & Treatment CRS, New York

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00028366 - Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People | Biotech Hunter | Biotech Hunter